Adagene Inc. (ADAG) Insider Trading Activity

NASDAQ$2
Market Cap
$75.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
256 of 846
Rank in Industry
146 of 490

ADAG Insider Trading Activity

ADAG Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$162,244
5
100
Sells
$0
0
0

Related Transactions

Luo PeterChief Executive Officer
3
$148,744
0
$0
$148,744
DO CUONG Vdirector
1
$7,500
0
$0
$7,500
Tam Man KinChief Financial Officer
1
$6,000
0
$0
$6,000

About Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Insider Activity of Adagene Inc.

Over the last 12 months, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of Adagene Inc. stock.

On average, over the past 5 years, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Luo Peter (Chief Executive Officer) — $148,744. DO CUONG V (director) — $7,500. Tam Man Kin (Chief Financial Officer) — $6,000.

The last purchase of 2,000 shares for transaction amount of $6,000 was made by Tam Man Kin (Chief Financial Officer) on 2026‑09‑23.

List of Insider Buy and Sell Transactions, Adagene Inc.

2026-09-23PurchaseTam Man KinChief Financial Officer
2,000
0.0054%
$3.00
$6,000
-14.31%
2026-09-16PurchaseLuo PeterChief Executive Officer
20,290
0.0536%
$3.15
$63,980
-15.46%
2026-08-14PurchaseDO CUONG Vdirector
2,000
0.0045%
$3.75
$7,500
-19.73%
2026-08-05PurchaseLuo PeterChief Executive Officer
279
0.0006%
$3.65
$1,018
-24.35%
2026-08-04PurchaseLuo PeterChief Executive Officer
22,966
0.0611%
$3.65
$83,746
-12.09%
Total: 5
*Gray background shows transactions not older than one year

ADAG Institutional Investors: Active Positions

Increased Positions8+40%1M+21.74%
Decreased Positions7-35%4M-67.74%
New Positions4New1MNew
Sold Out Positions4Sold Out4MSold Out
Total Postitions21+5%3M-46.01%

ADAG Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.